Analytical Data
-
Gene name
MLANA
- Application
-
Alternative Names
MLANA;MART1;Melanoma antigen recognized by T-cells 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q16655
-
Expression Region
1-118aa
-
AA Sequence
MPREDAHFIYGYPKKGHGHSYTTAEEAAGIGILTVILGVLLLIGCWYCRRRNGYRALMDKSLHVGTQCALTRRCPQEGFDHRDSKVSLQEKNCEPVVPNAPPAYEKLSAEQSPPPYSP
-
Molecular Weight
27.2kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MLANA, or Melanoma Antigen Located on Neoplasm Antigen, is a crucial protein implicated in the biology of melanoma, a highly aggressive form of skin cancer. Research into MLANA has gained momentum due to its roles in tumor growth, immune response, and potential as a target for immunotherapy. Melanoma cells often exhibit aberrant expression of MLANA, leading to its consideration as a tumor-associated antigen (TAA). Its expression can confer an immunogenic profile that may be leveraged for therapeutic interventions, such as cancer vaccines and adoptive T-cell therapies. The study of MLANA is not only vital for understanding the molecular mechanisms underlying melanoma progression but also opens avenues for developing targeted treatments that can enhance immune recognition and improve patient outcomes. Furthermore, ongoing investigations into the molecular structure and functional properties of MLANA aim to elucidate its interactions within the tumor microenvironment, which are critical for designing effective therapeutic strategies. As the incidence of melanoma continues to rise, the exploration of MLANA and its reconstituted proteins presents a promising direction for innovative cancer treatment modalities and aims to provide hope for improved survival rates among patients afflicted with this formidable disease.
